CA Patent

CA2485834C — Pseudopolymorphic forms of a hiv protease inhibitor

Assigned to Janssen Sciences Ireland ULC · Expires 2007-07-17 · 19y expired

What this patent protects

New pseudopolymorphic forms of (3R,3a S,6a R)-hexahydro-furo [2,3-b] furan-3-yl (1S,2R)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate of Formula (X) and processes for producing them are disclosed.

USPTO Abstract

New pseudopolymorphic forms of (3R,3a S,6a R)-hexahydro-furo [2,3-b] furan-3-yl (1S,2R)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate of Formula (X) and processes for producing them are disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
CA2485834C
Jurisdiction
CA
Classification
—
Expires
2007-07-17
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Sciences Ireland ULC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.